WO2005116250A3 - Viral and viral associated mirnas and uses thereof - Google Patents

Viral and viral associated mirnas and uses thereof Download PDF

Info

Publication number
WO2005116250A3
WO2005116250A3 PCT/IB2005/002352 IB2005002352W WO2005116250A3 WO 2005116250 A3 WO2005116250 A3 WO 2005116250A3 IB 2005002352 W IB2005002352 W IB 2005002352W WO 2005116250 A3 WO2005116250 A3 WO 2005116250A3
Authority
WO
WIPO (PCT)
Prior art keywords
viral
associated mirnas
mirnas
viral infections
methods
Prior art date
Application number
PCT/IB2005/002352
Other languages
French (fr)
Other versions
WO2005116250A8 (en
WO2005116250A2 (en
Inventor
Itzhak Bentwich
Amir Avniel
Original Assignee
Rosetta Genomics Ltd
Itzhak Bentwich
Amir Avniel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/709,739 external-priority patent/US7777022B2/en
Application filed by Rosetta Genomics Ltd, Itzhak Bentwich, Amir Avniel filed Critical Rosetta Genomics Ltd
Priority to AU2005248149A priority Critical patent/AU2005248149A1/en
Priority to JP2007514216A priority patent/JP2008500039A/en
Priority to CA002567937A priority patent/CA2567937A1/en
Priority to EP05774516A priority patent/EP1751311A2/en
Publication of WO2005116250A2 publication Critical patent/WO2005116250A2/en
Publication of WO2005116250A3 publication Critical patent/WO2005116250A3/en
Priority to US11/511,035 priority patent/US7795419B2/en
Priority to IL179545A priority patent/IL179545A/en
Publication of WO2005116250A8 publication Critical patent/WO2005116250A8/en
Priority to US12/850,091 priority patent/US8455633B2/en
Priority to US14/797,381 priority patent/US9624556B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/10—Production naturally occurring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16221—Viruses as such, e.g. new isolates, mutants or their genomic sequences

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)

Abstract

Described herein are novel polynucleotides associated with viral infections. The polynucleotides are miRNAs and miRNA precursors. Related methods and compositions that can be used for diagnosis, prognosis, and treatment of those medical conditions are disclosed. Also described herein are methods that can be used to identify modulators of viral infections.
PCT/IB2005/002352 2004-05-26 2005-05-26 Viral and viral associated mirnas and uses thereof WO2005116250A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
AU2005248149A AU2005248149A1 (en) 2004-05-26 2005-05-26 Viral and viral associated miRNAs and uses thereof
JP2007514216A JP2008500039A (en) 2004-05-26 2005-05-26 Viral miRNA and virus-related miRNA and uses thereof
CA002567937A CA2567937A1 (en) 2004-05-26 2005-05-26 Viral and viral associated mirnas and uses thereof
EP05774516A EP1751311A2 (en) 2004-05-26 2005-05-26 Viral and viral associated mirnas and uses thereof
US11/511,035 US7795419B2 (en) 2004-05-26 2006-08-28 Viral and viral associated miRNAs and uses thereof
IL179545A IL179545A (en) 2004-05-26 2006-11-23 Viral and viral associated mirnas and uses thereof
US12/850,091 US8455633B2 (en) 2004-05-26 2010-08-04 Viral and viral associated mirnas and uses thereof
US14/797,381 US9624556B2 (en) 2004-05-26 2015-07-13 Viral and viral associated miRNAs and uses thereof

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US10/709,739 2004-05-26
US10/709,739 US7777022B2 (en) 2002-12-05 2004-05-26 Bioinformatically detectable group of novel regulatory viral and viral associated oligonucleotides and uses thereof
US52245004P 2004-10-03 2004-10-03
US52245104P 2004-10-03 2004-10-03
US60/522,451 2004-10-03
US60/522,450 2004-10-03
US52245904P 2004-10-04 2004-10-04
US60/522,459 2004-10-04
US66509405P 2005-03-25 2005-03-25
US60/665,094 2005-03-25

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/709,739 Continuation-In-Part US7777022B2 (en) 2002-12-05 2004-05-26 Bioinformatically detectable group of novel regulatory viral and viral associated oligonucleotides and uses thereof

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US11/511,035 Continuation US7795419B2 (en) 2004-05-26 2006-08-28 Viral and viral associated miRNAs and uses thereof
US11/511,035 Continuation-In-Part US7795419B2 (en) 2004-05-26 2006-08-28 Viral and viral associated miRNAs and uses thereof

Publications (3)

Publication Number Publication Date
WO2005116250A2 WO2005116250A2 (en) 2005-12-08
WO2005116250A3 true WO2005116250A3 (en) 2006-07-06
WO2005116250A8 WO2005116250A8 (en) 2007-07-05

Family

ID=42331989

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2005/002352 WO2005116250A2 (en) 2004-05-26 2005-05-26 Viral and viral associated mirnas and uses thereof

Country Status (7)

Country Link
EP (1) EP1751311A2 (en)
JP (1) JP2008500039A (en)
CN (1) CN101031658A (en)
AU (1) AU2005248149A1 (en)
CA (1) CA2567937A1 (en)
IL (1) IL179545A (en)
WO (1) WO2005116250A2 (en)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040219565A1 (en) 2002-10-21 2004-11-04 Sakari Kauppinen Oligonucleotides useful for detecting and analyzing nucleic acids of interest
EP1851336B1 (en) * 2005-01-25 2010-09-08 Rosetta Inpharmatics LLC Methods for quantitating small rna molecules
US8071306B2 (en) 2005-01-25 2011-12-06 Merck Sharp & Dohme Corp. Methods for quantitating small RNA molecules
AU2006254732A1 (en) * 2005-06-03 2006-12-07 Southern Adelaide Health Service-Flinders Medical Centre Targeting cells with altered microrna expression
PT2007910T (en) * 2006-03-31 2016-12-30 Mobidiag Oy Method and microarray for detecting herpesviruses
US8007790B2 (en) 2006-04-03 2011-08-30 Stowers Institute For Medical Research Methods for treating polycystic kidney disease (PKD) or other cyst forming diseases
US7727725B2 (en) 2006-04-27 2010-06-01 Celera Corporation Genetic polymorphisms associated with liver fibrosis, methods of detection and uses thereof
WO2008029295A2 (en) * 2006-06-30 2008-03-13 Rosetta Genomics Ltd A method for detecting nucleic acids
US8227590B2 (en) 2006-11-21 2012-07-24 Jawaharlal Nehru Centre For Advanced Scientific Research High sensitivity assay for molecular typing of biological sample, probes and a kit thereof
SG143090A1 (en) * 2006-11-27 2008-06-27 Agency Science Tech & Res Influenza b virus detection method and kit therefor
WO2009024834A2 (en) * 2006-12-05 2009-02-26 Rosetta Genomics Ltd Nucleic acids involved in viral infection
US20100240049A1 (en) 2009-01-16 2010-09-23 Cepheid Methods of Detecting Cervical Cancer
EP2641976A3 (en) * 2009-01-16 2014-01-08 Cepheid Methods of detecting cervical cancer
AU2011205230A1 (en) 2010-01-13 2012-08-02 Caris Life Sciences Switzerland Holdings Gmbh Detection of gastrointestinal disorders
CN102791886B (en) * 2010-01-18 2015-04-08 乌得勒支大学控股有限公司 Means and methods for distinguishing FECV and FIPV
KR20130056855A (en) 2010-03-01 2013-05-30 카리스 라이프 사이언스 룩셈부르크 홀딩스 Biomarkers for theranostics
AU2011237669B2 (en) 2010-04-06 2016-09-08 Caris Life Sciences Switzerland Holdings Gmbh Circulating biomarkers for disease
KR101886457B1 (en) 2010-10-06 2018-08-07 큐알엔에이, 인크. Treatment of sialidase 4 (neu4) related diseases by inhibition of natural antisense transcript to neu4
AU2012308320C1 (en) 2011-09-14 2018-08-23 Translate Bio Ma, Inc. Multimeric oligonucleotide compounds
WO2013148868A1 (en) * 2012-03-30 2013-10-03 Intelligent Medical Devices, Inc. Optimized probes and primers and methods of using same for the binding, detection, differentiation, isolation and sequencing of herpes simplex virus
AU2013205110B2 (en) 2012-04-24 2016-10-13 Gen-Probe Incorporated Compositions, Methods and Kits to Detect Herpes Simplex Virus Nucleic Acids
WO2015191568A2 (en) 2014-06-09 2015-12-17 Biomed Valley Discoveries, Inc. Combination therapies using agents that target tumor-associated stroma or tumor cells and tumor vasculature
WO2015191596A1 (en) 2014-06-09 2015-12-17 Biomed Valley Discoveries, Inc. Combination therapies using platinum agents and agents that target tumor-associated stroma or tumor cells
US10758526B2 (en) 2014-06-09 2020-09-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services National Institutes Of Health Combination therapies using agents that target tumor-associated stroma or tumor cells and other pathways
US10758613B2 (en) 2014-06-09 2020-09-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services National Intstitutes Of Health Combination therapies using anti-metabolites and agents that target tumor-associated stroma or tumor cells
US10758614B2 (en) 2014-06-09 2020-09-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services National Institutes Of Health Combination therapies targeting tumor-associated stroma or tumor cells and topoisomerase
WO2015191590A2 (en) 2014-06-09 2015-12-17 Biomed Valley Discoveries, Inc. Combination therapies targeting tumor-associated stroma or tumor cells and microtubules
US10556020B2 (en) 2014-09-26 2020-02-11 University Of Massachusetts RNA-modulating agents
EP3256591A4 (en) * 2015-02-13 2018-08-08 Translate Bio Ma, Inc. Hybrid oligonucleotides and uses thereof
EP3313186A4 (en) 2015-06-29 2019-04-03 Biomed Valley Discoveries, Inc. Lpt-723 and immune checkpoint inhibitor combinations and methods of treatment
EP3411078A1 (en) * 2016-02-02 2018-12-12 Crispr Therapeutics AG Materials and methods for treatment of severe combined immunodeficiency (scid) or omenn syndrome
WO2017214378A1 (en) 2016-06-08 2017-12-14 President And Fellows Of Harvard College Engineered viral vector reduces induction of inflammatory and immune responses
JP2020529418A (en) 2017-07-31 2020-10-08 ザ トラスティーズ オブ コロンビア ユニバーシティ イン ザ シティ オブ ニューヨークＴｈｅ Ｔｒｕｓｔｅｅｓ Ｏｆ Ｃｏｌｕｍｂｉａ Ｕｎｉｖｅｒｓｉｔｙ Ｉｎ Ｔｈｅ Ｃｉｔｙ Ｏｆ Ｎｅｗ Ｙｏｒｋ Compounds, Compositions and Methods for Treating T-Cell Acute Lymphoblastic Leukemia
EP3707262A1 (en) 2017-11-08 2020-09-16 President and Fellows of Harvard College Compositions and methods for inhibiting viral vector-induced inflammatory responses
WO2019204864A1 (en) * 2018-04-23 2019-10-31 Simpori Pty Ltd A microbial sanitiser with broad applications
US11866705B2 (en) 2018-07-31 2024-01-09 Osaka Univerity Small cell lung cancer therapeutic agent containing oligonucleotide
US20210332367A1 (en) * 2018-09-18 2021-10-28 Alnylam Pharmaceuticals, Inc. KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
CA3211059A1 (en) 2021-02-26 2022-09-01 Alnylam Pharmaceuticals, Inc. Ketohexokinase (khk) irna compositions and methods of use thereof
US11578329B2 (en) 2021-04-19 2023-02-14 Novo Nordisk A/S Compositions and methods for inhibiting nuclear receptor subfamily 1 group H member 3 (NR1H3) expression
WO2023031418A1 (en) * 2021-09-03 2023-03-09 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Dna aptamers and their use in (pre)diagnosis of cancer
US11898186B1 (en) 2022-08-10 2024-02-13 Genscript Usa Inc. Compositions and methods for preparing capped mRNA

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
BARTEL D.P.: "MicroRNAs: Genomics, biogenesis, mechanism, and function.", CELL, vol. 116, no. 2, 23 January 2004 (2004-01-23), pages 281 - 297, XP002359089, ISSN: 0092-8674 *
CHANG J. ET AL.: "Resistance of human hepatitis delta virus RNAs to dicer activity.", JOURNAL OF VIROLOGY, vol. 77, no. 22, November 2003 (2003-11-01), pages 11910 - 11917, XP002360273, ISSN: 0022-538X *
DATABASE EMBL 11 March 2004 (2004-03-11), SAMULSKI R.J. ET AL.: "B19 parvovirus genomic DNA sequence", XP002359097, retrieved from EBI Database accession no. ADG39766 *
DATABASE EMBL 22 November 2001 (2001-11-22), SHOEMAKER R. ET AL., XP002359100, retrieved from EBI Database accession no. BM091632 *
DATABASE EMBL 8 October 2001 (2001-10-08), CLARK M. ET AL., XP002359099, retrieved from EBI Database accession no. BI843917 *
DATABASE EMBL 9 January 2003 (2003-01-09), PICHUANTES S. ET AL.: "Human parvovirus B19 PCR primer Hicks-5 SEQ ID NO:42", XP002359098, retrieved from EBI Database accession no. ABZ59584 *
DOENCH J.G. ET AL.: "Specificity of microRNA target selection in translational repression.", GENES & DEVELOPMENT, vol. 18, no. 5, 1 March 2004 (2004-03-01), pages 504 - 511, XP002359090, ISSN: 0890-9369 *
GRAD Y. ET AL.: "COMPUTATIONAL AND EXPERIMENTAL IDENTIFICATION OF C. ELEGANS MICRORNAS", MOLECULAR CELL, CELL PRESS, CAMBRIDGE, MA, US, vol. 11, no. 5, 1 May 2003 (2003-05-01), pages 1253 - 1263, XP009032050, ISSN: 1097-2765 *
KASSCHAU K.D. ET AL.: "P1/HC-PRO, A VIRAL SUPPRESSOR OF RNA SILENCING, INTERFERES WITH ARABIDOPSIS DEVELOPMENT AND MIRNA FUNCTION", DEVELOPMENTAL CELL, CAMBRIDGE, MA, US, vol. 4, no. 2, February 2003 (2003-02-01), pages 205 - 217, XP009037925, ISSN: 1097-4172 *
LEE R.C. ET AL.: "An extensive class of small RNAs in Caenorhabditis elegans", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 294, no. 5543, 26 October 2001 (2001-10-26), pages 862 - 864, XP002284273, ISSN: 0036-8075 *
LEWIS B.P.: "Prediction of Mammalian MicroRNA Targets", CELL, CELL PRESS, CAMBRIDGE, NA, US, vol. 115, no. 7, 26 December 2003 (2003-12-26), pages 787 - 798, XP002295226, ISSN: 0092-8674 *
PASQUINELLI A.E. ET AL.: "Conservation of the sequence and temporal expression of let-7 heterochronic regulatory RNA", NATURE, NATURE PUBLISHING GROUP, LONDON, GB, vol. 408, no. 6808, 2000, pages 86 - 89, XP002204652, ISSN: 0028-0836 *
PFEFFER S. ET AL.: "Identification of virus-encoded microRNAs", SCIENCE (WASHINGTON D C), vol. 304, no. 5671, 30 April 2004 (2004-04-30), pages 734 - 736, XP002360918, ISSN: 0036-8075 *

Also Published As

Publication number Publication date
EP1751311A2 (en) 2007-02-14
CA2567937A1 (en) 2005-12-08
AU2005248149A1 (en) 2005-12-08
JP2008500039A (en) 2008-01-10
WO2005116250A8 (en) 2007-07-05
CN101031658A (en) 2007-09-05
IL179545A (en) 2010-12-30
WO2005116250A2 (en) 2005-12-08
IL179545A0 (en) 2007-05-15

Similar Documents

Publication Publication Date Title
WO2005116250A3 (en) Viral and viral associated mirnas and uses thereof
WO2005111211A3 (en) Micronas and uses thereof
EP2325333A8 (en) MicrorRNAs and uses thereof
WO2009108866A3 (en) Microrna signatures associated with cytogenetics and prognosis in acute myeloid leukemia (aml) and uses thereof
WO2009108856A3 (en) Microrna signatures associated with human chronic lymphocytic leukemia (ccl) and uses thereof
WO2007148235A3 (en) Cancer-related nucleic acids
WO2010018563A3 (en) Compositions and methods for the prognosis of lymphoma
WO2009105513A3 (en) Novel compounds and methods for therapy
AU2008298744A8 (en) MiRNA expression in human peripheral blood microvesicles and uses thereof
WO2008127364A3 (en) Antiviral compounds and use thereof
WO2009129246A3 (en) Compositions and methods for preparing and using same
WO2008115281A3 (en) Compounds for treating viral infections
WO2008066784A3 (en) Expression of foxp3 by cancer cells
WO2008027600A3 (en) Imatinib compositions
WO2009120712A3 (en) Compositions and methods for diagnosing and treating melanoma
WO2011159693A3 (en) Oral treatment of digital ischemic lesions
WO2006091861A3 (en) Compositions and methods relating to cns lymphoma
WO2011130426A3 (en) Compositions and methods for treatment of melanoma
WO2008092099A8 (en) Compositions and methods for treating hematopoietic malignancies
WO2011021177A3 (en) Compositions and methods for prognosis and treatment of prostate cancer
WO2009098464A3 (en) Use of g-rich oligonucleotides for treating neoplastic diseases
WO2007062380A3 (en) Modulation of eif4e-bp2 expression
WO2020231997A9 (en) Non-coding rna for subtyping of bladder cancer
WO2009147658A3 (en) Compositions and methods for diagnosis, prognosis and treatment of mesothelioma
WO2010058393A3 (en) Compositions and methods for the prognosis of colon cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 11511035

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2567937

Country of ref document: CA

Ref document number: 179545

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2007514216

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 2005248149

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 7427/DELNP/2006

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2005774516

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2005248149

Country of ref document: AU

Date of ref document: 20050526

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 11511035

Country of ref document: US

Ref document number: 2005248149

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 200580025300.4

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2005774516

Country of ref document: EP